Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Recombinant Hepatitis E Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy people aged from 16 years to 65 years old at the time of the first vaccination, normal intelligence and agree to sign the informed consent form.~* Subjects will reside in the study region in the next 19 months.~* Free of history of hepatitis B or hepatitis E.~* Can comply with the request of study.~* Axillary temperature is below 37 degree centigrade.~Exclusion Criteria:~For dose 1:~* Having other vaccine or immunoglobulin within two weeks;~* Having allergic history to vaccine and medicine~* Eclampsia, epilepsy, encephalopathy and history of mental disease or family;~* Thrombocytopenia or other disturbance of blood coagulation which would lead to muscle injection taboo;~* Fixed or suspected deficiency of immunologic function, containing immunosuppressant treatment(radiation therapy, chemical treatment, steroid hormone, antimetabolites, cytotoxic drugs), genetic defect(e.g. fabism), HIV or other factors;~* congenital malformation, eccyliosis or severe chronic disease(e.g. Down Syndrome, diabetes, sickle cell anemia or mental disease);~* fixed or suspected other disease including fever, active infection, liver and kidney disease, angiocardiopathy, malignancy, acute and chronic disease;~* joining other clinical study undergoing;~* women pregnant or in lactation.~For dose 2 or 3:~* Severe allergy for dose 1 or 2;~* Severe adverse reaction associated with last vaccination;~* New occurrence of symptoms meet dose 1 exclusion criteria after the first dose.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Hepatitis E vaccine (Type: EXPERIMENTAL): Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
- HBV vaccine (Type: PLACEBO_COMPARATOR): Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).